Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Roberts

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
Ecology and Evolution|December 15, 2015
Testing projected wild bee distributions in agricultural habitats: predictive power depends on species traits and habitat typeLeon Marshall, Luísa G Carvalheiro, Jesús Aguirre-Gutiérrez, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 30, 2016
Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapyLucy Lim, Alexander Thompson, Scott Patterson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 22, 2022
Noninvasive Assessment of Acute Graft-Versus-Host Disease of the Gastrointestinal Tract After Allogeneic Hemopoietic Stem Cell Transplantation Using <sup>18</sup>F-FDG PETMartin H Cherk, Robert Khor, Thomas W Barber, et al.
BMC Public Health|May 31, 2018
Longitudinal study of health, disease and access to care in rural Victoria: the Crossroads-II study: methodsKristen M Glenister, Lisa Bourke, Leslie Bolitho, et al.
Plos Pathogens|December 31, 2009
Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infectionShuo Li, Stefan Floess, Alf Hamann, et al.
Plos One|August 21, 2012
Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individualsShuo Li, Stuart Roberts, Magdalena Plebanski, et al.
Antiviral Therapy|March 31, 2011
Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patientsCristina Baleriola, William D Rawlinson, Gregory J Dore, et al.
Alimentary Pharmacology & Therapeutics|March 3, 2025
Patient Reported Outcomes in Primary Sclerosing Cholangitis: An Australian PerspectiveNatassia Tan, Christopher Zampogna, Kate Lynch, et al.
Journal of Hepatology|November 28, 2012
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failureGraham R Foster, Stefan Zeuzem, Pietro Andreone, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2014
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE studyThomas Berg, Pietro Andreone, Stanislas Pol, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Ecology and Evolution|December 15, 2015
Testing projected wild bee distributions in agricultural habitats: predictive power depends on species traits and habitat typeLeon Marshall, Luísa G Carvalheiro, Jesús Aguirre-Gutiérrez, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 30, 2016
Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapyLucy Lim, Alexander Thompson, Scott Patterson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 22, 2022
Noninvasive Assessment of Acute Graft-Versus-Host Disease of the Gastrointestinal Tract After Allogeneic Hemopoietic Stem Cell Transplantation Using <sup>18</sup>F-FDG PETMartin H Cherk, Robert Khor, Thomas W Barber, et al.
BMC Public Health|May 31, 2018
Longitudinal study of health, disease and access to care in rural Victoria: the Crossroads-II study: methodsKristen M Glenister, Lisa Bourke, Leslie Bolitho, et al.
Plos Pathogens|December 31, 2009
Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infectionShuo Li, Stefan Floess, Alf Hamann, et al.
Plos One|August 21, 2012
Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individualsShuo Li, Stuart Roberts, Magdalena Plebanski, et al.
Antiviral Therapy|March 31, 2011
Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patientsCristina Baleriola, William D Rawlinson, Gregory J Dore, et al.
Alimentary Pharmacology & Therapeutics|March 3, 2025
Patient Reported Outcomes in Primary Sclerosing Cholangitis: An Australian PerspectiveNatassia Tan, Christopher Zampogna, Kate Lynch, et al.
Journal of Hepatology|November 28, 2012
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failureGraham R Foster, Stefan Zeuzem, Pietro Andreone, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2014
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE studyThomas Berg, Pietro Andreone, Stanislas Pol, et al.
Pageof 7